Bellerophon Therapeutics LLC Stock Nasdaq
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
Apr. 25 | North American Morning Briefing : More Tech -2- | DJ |
Apr. 11 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
Sales 2021 | - | Sales 2022 | - | Capitalization | 8.59M 0 |
---|---|---|---|---|---|
Net income 2021 | -17M - | Net income 2022 | -19M - | EV / Sales 2021 | - |
Net cash position 2021 | 23.78M 0 | Net cash position 2022 | 6.72M 0 | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.66
x | P/E ratio 2022 |
-0.43
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 84.97% |
Latest transcript on Bellerophon Therapeutics LLC
Managers | Title | Age | Since |
---|---|---|---|
Craig Jalbert
CEO | Chief Executive Officer | 63 | - |
Martin Dekker
CTO | Chief Tech/Sci/R&D Officer | 51 | 15-01-28 |
Edwin L. Parsley
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Naseem Amin
CHM | Chairman | 62 | 15-06-28 |
1st Jan change | Capi. | |
---|---|---|
-1.92% | 103B | |
+0.57% | 95.71B | |
+1.69% | 22.02B | |
-17.25% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.94% | 15.52B | |
+3.27% | 13.86B | |
+35.57% | 12.04B |